202 related articles for article (PubMed ID: 22736220)
1. Correlation between biological activity and binding energy in systems of integrin with cyclic RGD-containing binders: a QM/MM molecular dynamics study.
Xiang M; Lin Y; He G; Chen L; Yang M; Yang S; Mo Y
J Mol Model; 2012 Nov; 18(11):4917-27. PubMed ID: 22736220
[TBL] [Abstract][Full Text] [Related]
2. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
Choi Y; Kim E; Lee Y; Han MH; Kang IC
Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD and
Panzeri S; Arosio D; Gazzola S; Belvisi L; Civera M; Potenza D; Vasile F; Kemker I; Ertl T; Sewald N; Reiser O; Piarulli U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339382
[TBL] [Abstract][Full Text] [Related]
4. Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands.
Marchini M; Mingozzi M; Colombo R; Guzzetti I; Belvisi L; Vasile F; Potenza D; Piarulli U; Arosio D; Gennari C
Chemistry; 2012 May; 18(20):6195-207. PubMed ID: 22517378
[TBL] [Abstract][Full Text] [Related]
5. Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.
Cini N; Trabocchi A; Menchi G; Bottoncetti A; Raspanti S; Pupi A; Guarna A
Bioorg Med Chem; 2009 Feb; 17(4):1542-9. PubMed ID: 19195898
[TBL] [Abstract][Full Text] [Related]
6. Combined QM/MM study of thyroid and steroid hormone analogue interactions with αvβ3 integrin.
Freindorf M; Furlani TR; Kong J; Cody V; Davis FB; Davis PJ
J Biomed Biotechnol; 2012; 2012():959057. PubMed ID: 22547930
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.
Liu S
Bioconjug Chem; 2009 Dec; 20(12):2199-213. PubMed ID: 19719118
[TBL] [Abstract][Full Text] [Related]
8. Structure-Activity Relationship of RGD-Containing Cyclic Octapeptide and αvβ3 Integrin Allows for Rapid Identification of a New Peptide Antagonist.
Silva A; Xiao W; Wang Y; Wang W; Chang HW; Ames JB; Lam KS; Zhang Y
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349271
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.
Yu YP; Wang Q; Liu YC; Xie Y
Biomaterials; 2014 Feb; 35(5):1667-75. PubMed ID: 24268666
[TBL] [Abstract][Full Text] [Related]
10. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling of the thyroid hormone interactions with alpha v beta 3 integrin.
Cody V; Davis PJ; Davis FB
Steroids; 2007 Feb; 72(2):165-70. PubMed ID: 17166537
[TBL] [Abstract][Full Text] [Related]
12. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
13. Identification of the principal binding site for RGD-containing ligands in the alpha(V)beta(3) integrin: a photoaffinity cross-linking study.
Yahalom D; Wittelsberger A; Mierke DF; Rosenblatt M; Alexander JM; Chorev M
Biochemistry; 2002 Jul; 41(26):8321-31. PubMed ID: 12081480
[TBL] [Abstract][Full Text] [Related]
14. Photocontrol of cell adhesion processes: model studies with cyclic azobenzene-RGD peptides.
Schütt M; Krupka SS; Milbradt AG; Deindl S; Sinner EK; Oesterhelt D; Renner C; Moroder L
Chem Biol; 2003 Jun; 10(6):487-90. PubMed ID: 12837381
[TBL] [Abstract][Full Text] [Related]
15. Interaction Mechanism and Clustering among RGD Peptides and Integrins.
Dong X; Yu Y; Wang Q; Xi Y; Liu Y
Mol Inform; 2017 May; 36(5-6):. PubMed ID: 28004516
[TBL] [Abstract][Full Text] [Related]
16. Combining pharmacophore search, automated docking, and molecular dynamics simulations as a novel strategy for flexible docking. Proof of concept: docking of arginine-glycine-aspartic acid-like compounds into the alphavbeta3 binding site.
Moitessier N; Henry C; Maigret B; Chapleur Y
J Med Chem; 2004 Aug; 47(17):4178-87. PubMed ID: 15293990
[TBL] [Abstract][Full Text] [Related]
17. Fluorometric assay of integrin activity with a small-molecular probe that senses the binding site microenvironment.
Komatsu T; Takeda A; Hanaoka K; Terai T; Ueno T; Tada Y; Nagano T; Urano Y
Chem Commun (Camb); 2014 Dec; 50(100):15894-6. PubMed ID: 25376090
[TBL] [Abstract][Full Text] [Related]
18. Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
Casiraghi G; Rassu G; Auzzas L; Burreddu P; Gaetani E; Battistini L; Zanardi F; Curti C; Nicastro G; Belvisi L; Motto I; Castorina M; Giannini G; Pisano C
J Med Chem; 2005 Dec; 48(24):7675-87. PubMed ID: 16302808
[TBL] [Abstract][Full Text] [Related]
19. Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design.
Marinelli L; Lavecchia A; Gottschalk KE; Novellino E; Kessler H
J Med Chem; 2003 Oct; 46(21):4393-404. PubMed ID: 14521404
[TBL] [Abstract][Full Text] [Related]
20. Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.
Zanardi F; Burreddu P; Rassu G; Auzzas L; Battistini L; Curti C; Sartori A; Nicastro G; Menchi G; Cini N; Bottoncetti A; Raspanti S; Casiraghi G
J Med Chem; 2008 Mar; 51(6):1771-82. PubMed ID: 18303826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
